The tyrosine kinase (TK) family is an important regulator of signaling pathways that control a variety of physiological and pathological conditions, and a substantial proportion of TK genes are genetically altered in cancer. To clarify the somatic mutation profile of TK genes and discover potential targets for gastric cancer (GC) therapy, we undertook a systematic screening of mutations in the kinase domains of all human TK genes (636 exons of 90 genes) in 17 GC cell lines and 52 microdissected primary GCs with poorly differentiated histology. We identified 26 nonsynonymous alterations (22 genes in total) that included 11 sequence alterations in cell lines and 15 somatic mutations in primary tumors. Recurrent mutations were found in four genes including a known oncogene (NTRK3), the Src kinase family (LTK and CSK) and a potential Wnt signal activator (ROR2). In addition, we analyzed copy number alterations of all the TK gene loci in the same cohort samples by array-based comparative genomic hybridization analysis and identified 24 high-level amplifications and two homozygous deletions. Both sequence alteration and frequent copy number aberration were detected in two TK genes (HCK and ERBB2), strongly suggesting that they encode potential oncogenes in GC. Our focused and integrated analyses of systemic resequencing and gene copy number have revealed the novel onco-kinome profile of GC and pave the way to a comprehensive understanding of the GC genome.
The tyrosine kinase (TK) family is an important regulator of signaling pathways that control a variety of physiological and pathological conditions, and a substantial proportion of TK genes are genetically altered in cancer. To clarify the somatic mutation profile of TK genes and discover potential targets for gastric cancer (GC) therapy, we undertook a systematic screening of mutations in the kinase domains of all human TK genes (636 exons of 90 genes) in 17 GC cell lines and 52 microdissected primary GCs with poorly differentiated histology. We identified 26 nonsynonymous alterations (22 genes in total) that included 11 sequence alterations in cell lines and 15 somatic mutations in primary tumors. Recurrent mutations were found in four genes including a known oncogene (NTRK3), the Src kinase family (LTK and CSK) and a potential Wnt signal activator (ROR2). In addition, we analyzed copy number alterations of all the TK gene loci in the same cohort samples by array-based comparative genomic hybridization analysis and identified 24 high-level amplifications and two homozygous deletions. Both sequence alteration and frequent copy number aberration were detected in two TK genes (HCK and ERBB2), strongly suggesting that they encode potential oncogenes in GC. Our focused and integrated analyses of systemic resequencing and gene copy number have revealed the novel onco-kinome profile of GC and pave the way to a comprehensive understanding of the GC genome.
Introduction
Gastric cancer (GC) is the second most common cause of cancer death worldwide (1), with an incidence of 0.14% per year in Japan (2) . Infection with Helicobacter pylori is reportedly a strong epidemiological risk factor for GC (3) . In spite of the recent progress in preventive, diagnostic and therapeutic modalities, the prognosis of GC, especially poorly differentiated or diffuse-type adenocarcinoma, is still poor (4) . Genetic aberrations of multiple genes (CDH1, APC, CTNNB1, CDKN2A and KRAS) in GC have been reported, but the mutation frequencies of these genes are less than $20%, as summarized in the Catalogue of Somatic Mutations in Cancer (COSMIC) database, indicating the complexity of the carcinogenetic pathways in GC (5) . Genomic instability and copy number aberrations (CNAs) in GC cell lines and primary tumor samples have also been investigated using array-based comparative genomic hybridization (array-CGH) (6) (7) (8) . Thus, the GC genome seems to be highly complex, and comprehensive analysis will be required for efficient identification of the key oncogenic molecular pathways.
Since the completion of sequencing of the human genome, genomewide screenings of somatic mutations in several cancers have been performed (9) (10) (11) . These studies have revealed that numerous somatic mutations (including functional 'driver mutation' and non-functional/ neutral 'passenger mutation') exist in a wide range of genes, and that the distribution of cancer-related genes differs in each cancer type and even in individual cancer samples (12, 13) . Among various gene families, the protein kinase gene family has been examined intensively because somatic mutations and copy number alterations in this family are most frequently present in many cancer types (14) and are also good potential targets for molecular therapy (15) . However, no systematic analysis of both somatic mutations and copy number alterations of the kinase family in GC has yet been reported.
The tyrosine kinase (TK) family constitutes a large group within the protein kinase family, and 90 genes encoding TKs have been identified in the human genome (16) . TKs are important regulators of intercellular signaling pathways that control a variety of physiological and pathological conditions such as differentiation, cell cycle progression, survival and motility, and a substantial proportion of TK genes have been shown to be genetically altered in specific types of cancer (17) . Somatic mutations of TK genes (FGFR2, ERBB2 and ERBB4) have been reported previously in GC (18) (19) (20) .
Since genome-wide systematic profiling of somatic mutations by resequencing analysis will be beneficial for a comprehensive understanding of molecular events and identification of novel therapeutic targets in GC, we conducted a resequencing analysis of kinase domains in the 90 TK genes in 52 specimens of primary GC and 17 GC cell lines. Because of its clinical importance, we focused on poorly differentiated GC, and therefore most of the analyzed primary samples and all cell lines were derived from poorly differentiated adenocarcinoma including the scirrhous and signet-ring cell types. As poorly differentiated GC tissues often contain abundant non-cancerous stromal cells, precise mutation screening using genomic DNA from a tissue block is challenging, as is the case for other stroma-rich solid tumors. To overcome this difficulty, we prepared high-purity cancer genomic DNA with the use of laser capture microdissection and whole-genomic amplification (WGA). Moreover, we determined the copy number status of all TK gene loci in the same samples using array-CGH.
Materials and methods
Cancer specimens Seventeen GC cell lines were cultured under appropriate conditions. Cell lines HSC-44, HSC-45, HSC-58, HSC-59, HSC-60 and HSC-64 were established at our institution and have been previously characterized (21) . Other cell lines were obtained commercially. Primary tumor specimens from 52 Japanese patients who had been diagnosed and undergone surgery at the National Cancer Center Hospital, Tokyo, Japan, between January 1998 and August 2001 were examined. Clinical information for the analyzed cases is shown in Supplementary Table SI (available at Carcinogenesis Online). The histological classification of GCs is based on the policy by Japanese Gastric Cancer Association; poorly differentiated adenocarcinoma includes signet-ring cell carcinoma (sig), poorly differentiated tubular adenocarcinoma [solid type (por1) and non-solid type (por2)] and mucinous adenocarcinoma (muc) (22) . The diffuse-type GC is equivalent to the sig and por2 subtypes and the intestinal type includes por1 and muc subtypes. This study was approved by the institutional review board of the National Cancer Center.
DNA extraction and WGA
Tumor cells in methanol-fixed paraffin-embedded specimens were subjected to laser capture microdissection (23) using the LM200 system (Arcturus, Mountain View, CA). Tumor-derived genomic DNA was prepared from the microdissected cells after proteinase K treatment in lysis buffer (10 mM Tris-HCl, pH 7.5, 1 mM ethylenediamine tetraacetic acid and 0.5% sodium dodecylsulfate) and purified by the standard phenol-chloroform extraction method. WGA of the DNA from tumor cells was performed by polymerase chain reaction (PCR), using the PCR for random shared genomic DNA method without DNA sharing, as described previously (24) . Two high-fidelity DNA polymerases, Ex-Taq (Takara Bio, Shiga, Japan) and KOD plus (Toyobo, Osaka, Japan), were used for mutation screening and validation, respectively. Corresponding normal genomic DNA was extracted from patient-matched lymph node specimens as a reference. Genomic DNA was extracted by the standard method from cell lines, and the DNA was amplified using the REPLI-g Mini Kit (Qiagen, Hilden, Germany).
Primer design and PCR sequencing
Information about the genome sequences of the 90 TKs, KRAS and BRAF genes was collected from the GenBank database (25) at the National Institutes of Health. Primers for PCR and sequencing were designed to amplify the selected exons and the flanking intronic sequences using the OLIGO 6 software package (26) . The complete 643-primer set was synthesized and optimized for 636 exons encoding the kinase domain of the 90 TK genes, exons 1 and 2 of KRAS and exon 15 of BRAF (all primers are listed in Supplementary Table SII, available at Carcinogenesis Online). PCR was performed in a 10 ll volume containing 0.5 units of KOD plus DNA polymerase, 12.5 ng of genomic DNA, 5 pmol of each PCR primer and 5 lmol of deoxyribonucleotide triphosphates. The thermocycling was performed at 94°C for 2 min followed by 35 cycles of 94°C for 15 s, annealing at an optimized temperature for 30 s and 68°C for 30 s. The remaining primers and deoxyribonucleotide triphosphates in the reaction mixture were removed by MultiScreen PCRl96 (Millipore, Danvers, MA) in accordance with the manufacturer's instructions. The sequencing reaction was performed using 1 ll of the purified PCR product, 0.53 ll of BigDye version 1.1 (Applied Biosystems, Foster City, CA), 5Â sequencing buffer (Applied Biosystems) and 1.5 lmol of primer in a 10 ll volume. The thermocycling was performed at 96°C for 1 min followed by 25 cycles of 96°C for 20 s, 56 (or 50)°C for 10 s and 60°C for 1.5 min. All sequencing reactions were performed in both the forward and reverse directions. The sequencing product was purified by CleanSeq (Agencourt Bioscience, Beverly, MA) in accordance with the manufacturer's instructions. All chromatograms were detected using an ABI Prism 3700 DNA analyzer (Applied Biosystems).
Mutation screening
Alignment of DNA sequences was performed using SEQUENCHER software (27). To exclude the known single-nucleotide polymorphisms (SNPs), candidate mutations were compared with the SNP database (dbSNP) (28). For confirmation of reproducibility, exons containing candidate mutations were sequenced with an independently prepared set of genomic DNA. Somatic mutations were identified by comparison with the sequence of paired normal DNA.
Array-CGH analysis
Two array-CGH platforms were used in this study. A high-resolution SNP array, the Affymetrix Mapping 50K-Xba array (Affymetrix, Santa Clara, CA), was used to analyze allelic imbalances in GC cell lines. Chromosome copy number was calculated using CNAG 2.0 (29) . For data normalization, we used five normal reference samples. The genomic location of probes on the array was determined using the information in National Center for Biotechnology Information genome map build 35. Because XbaI digestion is not applicable for PCR for random shared genomic DNA method-amplified DNA samples, a high-resolution bacterial artificial chromosome array, MCG Whole Genome Array-4500 (30) , was used alternatively to analyze allelic imbalances in primary tumor samples. Tumor DNAs and paired normal DNAs were amplified by the PCR for random shared genomic DNA method and labeled with Cy3-and Cy5-dCTP, respectively. The hybridization methods were modified and carried out as described elsewhere (31) . Intensity data for SNP probes or bacterial artificial chromosome clones located in each TK gene region or the nearest neighbor region were extracted and used for CNA analysis. Independently defined values for CNA criteria were optimized for each T.Kubo et al.
array-CGH system. The test/control intensity ratio in the SNP array was defined as high-level amplification (log2ratio .1.5), gain (log2ratio .0.35), loss (log2ratio ,À0.35) or homozygous deletion (HD) (log2ratio ,À1.5), respectively. The tumor/normal intensity ratio in the bacterial artificial chromosome array was defined as high-level amplification (.2), gain (.1.3), loss (,0.7) or HD (,0.4), respectively, as validated in the previous study (31) .
Results

Confirmation of KRAS and BRAF mutations in GC samples
To validate the sample DNA quality for sequence analysis, we first determined the KRAS and BRAF mutations, both of which are reported to occur in a fraction of GC. KRAS mutations were detected in 3 of 17 (17.6%) cell lines and in 8 of 52 (15.4%) primary tumor samples (Supplementary Table SI is available at Carcinogenesis Online). All KRAS mutations were heterozygous and most of them occurred at hot spots (codons 12, 13 and 61). Exceptionally, one primary tumor sample (GC008) contained a p.L19F somatic mutation. This rare mutation was identified in colon cancer and has been reported to possess oncogenic activity (32) . In contrast, no BRAF mutation was found in either the cell lines or primary cancer samples.
Screening for DNA alterations of TK genes in GC cell lines We then amplified exons encoding the kinase domain in the 90 TK genes from 17 GC cell lines and determined their sequences in both directions. In our screening, .88 kb of the genomic DNA, which contains 636 exons encoding the kinase domain (including four pseudokinase domains) in 90 TK genes, was examined in each specimen and $93% of the total sequence was determined. We identified 11 non-synonymous and 18 synonymous DNA alterations that were not registered in the dbSNP (Table I ) (28), although these DNA alterations potentially contained rare SNPs. Chromatograms of 11 non-synonymous DNA alterations are shown with other wild-type chromatograms in Figure 1 . In the 11 non-synonymous alterations, LTK p.L844I was identified in the flanking C-terminal region of the kinase domain.
Screening for somatic mutations of TK genes in primary GCs
We next sequenced 636 exons in 52 cases of primary gastric adenocarcinoma. To exclude PCR-mediated errors, candidate mutations were confirmed by sequencing independently amplified samples. Somatic mutations were determined by analyzing the corresponding normal DNA. We identified 19 somatic mutations in 18 genes (Table  II) . Fifteen mutations were non-synonymous, and these chromatograms are shown with the chromatograms of each paired normal sample in Figure 2 . Two non-synonymous mutations of IGF1R (p.M1300I) and KDR (p.V805I) were identified in the flanking C-terminal regions of each kinase domain. Combined with the data of the cell lines, recurrent non-synonymous alterations were identified in four TK genes (CSK, LTK, NTRK3 and ROR2), but no mutational hot spot was so far found in kinase domain of 90 TK genes (Tables I and II) . Amino acid positions encoded by non-synonymous DNA alterations and somatic mutations detected in our resequencing analysis are summarized in Figure 3 . Two alterations (HEK p.A382V and ROR2 p.D644N) and two somatic mutations (EPHA1 p.Y781C and EPHA2 p.R782C) were identified in the activation segment region. Resequencing and copy number analysis of the human TK gene family in poorly differentiated GC 
Array-CGH analysis of TK gene loci in GC cell lines and primary tumor samples
To further determine CNAs of the 90 TK genes in GC, we performed array-CGH analysis of 16 GC cell lines and 51 primary GC samples that were analyzed by resequencing as described above. The frequencies of the CNAs in the 90 TK genes are shown in Supplementary Table SIII (available at Carcinogenesis Online), and high-level amplifications, HDs and frequent gain or loss of TK gene regions are shown in Table III . High-level amplifications and HDs were identified at 24 and 2 TK gene loci, respectively. Five TK genes (HCK, TIE1, TEK, ERBB2 and BTK) which harbored non-synonymous DNA alterations or somatic mutations were found to be recurrently amplified in GC. Moreover, frequent gain of the HCK and ERBB2 genes (50.8 and 36.5%, respectively) was observed in GC.
Discussion
In the present study, we conducted targeted resequencing and copy number analyses of GC by preparing highly purified cancer DNA from primary tumor samples containing abundant stromal cells. To evaluate the feasibility of our WGA for large-scale resequencing analysis, we focused on the kinase domains of the TK gene family, which includes known oncogenes and clinically validated therapeutic targets.
A previous mutation analysis of 319 GC samples revealed KRAS and BRAF mutations in 2.8 and 2.2% of the examined cases, respectively (33) , and the frequency of KRAS mutation in GC registered in the COSMIC database is 6% (5). In the present study, we identified KRAS mutation in 15.9% of the analyzed samples (17.6% of cell lines and 15.4% of GCs). This difference might have been because our samples predominantly included poorly differentiated cancer. However, since we detected a similar frequency of KRAS mutation in both cell lines and primary tumors, our result strongly argues that our genomic DNA preparation method is efficient and applicable for mutation screening of primary tumors, especially those such as poorly differentiated GC containing plentiful stromal cells. In contrast to KRAS, no BRAF mutation was observed in our present analysis. This discrepancy between the two studies might be explained by the distinct fraction of histological/molecular subtypes analyzed (34) , but further studies will be required to clarify this.
Previous genetic screenings of GC cell lines and primary tumors have identified non-synonymous mutations of individual TK genes (FGFR2, FGFR3, ERBB2 and ERBB3) (18) (19) (20) . In addition, a large-scale resequencing study of 518 human kinase genes in 18 samples of primary GC revealed 18 non-synonymous mutations in 90 TK genes (13) . Eleven of these mutations were discovered in two GC specimens, which were mismatch repair-deficient cancers. However, the molecular alteration profile of the TK genes in GC, especially poorly differentiated subtypes, has not been sufficiently understood. Resequencing and copy number analysis of the human TK gene family in poorly differentiated GC We identified 29 DNA alterations and 19 somatic mutations in 17 cell lines and 52 primary cancers, respectively (Tables I and II) . We detected the same DNA alterations in two gastric cell lines (HSC 43 and 44) that had been established from the pleural effusion and ascitic tumor of a single patient. This validates the accuracy of our genome amplification and sequencing procedures. The frequency of TK kinase domain mutation is comparable to that of other tumor types reported in previous studies (9) (10) (11) (12) 35) ; the overall frequency of TK kinase domain mutations in various cancers (breast, lung, testis, colon and pancreas) is 0-0.46 mutation per sample and that revealed by our analysis is 0.36 mutation per primary GC specimen.
In total, we identified 26 non-synonymous DNA alterations and somatic mutations. Among them, four TK genes (CSK, NTRK3, LTK and ROR2) harbored recurrent non-synonymous alterations, although no hot spot mutation was detected. These four genes may include potential oncogenes in GC. Indeed NTRK3 is a wellknown oncogene in various cancers (mutations in medulloblastoma, breast, lung and colon cancers and a translocation in fibrosarcoma have been reported) (9,10,36), but no NTRK3 mutation has been reported in primary GC. CSK is known to act as a negative regulator of SRC oncogenic kinase and the other Src family kinases (SFKs) through phosphorylation of these C-terminal regulatory tyrosines (37), while LTK encodes one of the SFKs. Although SFKs are implicated in various types of signaling, including that involved in cancer cell proliferation, migration and metastasis (38) , no evidence has been reported for molecular alterations of this family in GC, and therefore further studies will be required to clarify whether these mutations result in loss or gain of function. ROR2 encodes a receptor-type TK and no reported study has yet investigated its role in human carcinogenesis. Interestingly, a recent study revealed that Wnt5a, which is involved in oncogenesis and multiple developmental processes, activates ROR2 (39) . Since aberrant Wnt signaling caused by genetic and epigenetic alterations of CDH1, APC and CTNNB1 in GC has been studied extensively (40) , oncogenic aberration of ROR2 (see below) may also be implicated in this signaling.
Since most of the identified alterations occurred in the single gene, we further compared them with previously reported mutations registered in the COSMIC database. Only one non-synonymous somatic mutation of EPHA6 (p.K813N) was matched to the one registered in the COSMIC database as a somatic mutation found in a GC sample (MutID: 21280). To predict the functional effects of other previously uncharacterized mutations, we then allocated each mutation in the kinase domain. The common molecular structure and functional role of each subdomain in the protein kinase domain are well characterized (41, 42) . Our screening revealed two sequence alterations (HEK pA382V and ROR2 p.D644N) and two somatic mutations (EPHA1 p.Y781C and EPHA2 p.R782C) in the activation segment region, which contains tyrosine residues indispensable for kinase activation ( Figure 3) . Thus, it is plausible to expect that these 'activation segment' mutations affect the kinase activity and may act as a driver mutation in each GC. Other alterations such as one (p.K756R) localized in the pseudokinase domain of JAK1 might also affect its kinase activity since that domain has a role in substrate recognition (43) .
To allow an overall interpretation of both sequence and CNAs, which are the major genetic alterations occurring in solid tumors, for the TK gene family in GC, we also carried out array-CGH analysis of the same specimens (F.Hosoda, Y.Arai, T.Shibata, in preparation) that had been resequenced. In this study, we focused on copy number changes in the TK gene loci and found 24 high-level amplifications and 2 HDs. Among the frequently amplified TK genes (PTK7, SRMS, MET, PTK6), high-level amplification of PTK7 and MET has been reported in GC (44, 45) . Over-expression of PTK6 (also known as BRK) has been observed in several cancers such as those of the breast, colon and prostate, as well as melanoma, and over-expression of Brk cooperated with that of ErbB2 during murine mammary tumorigenesis (46) . Five TK genes (HCK, TIE1, TEK, ERBB2 and BTK) harbored both non-synonymous DNA alteration and gene amplification in GC. Moreover, gain of the HCK and ERBB2 genes was frequently observed (50.8 and 36.5%, respectively), strongly suggesting that these two TKs encode potential oncogenes in GC. High-level amplification of the ERBB2 gene has been frequently (17-21%) observed in GC (7, 8, 47) . However, we detected only one case with ERBB2 amplification probably because the present study focused on the poorly differentiated GC. Indeed a previous study has detected one ERBB2 amplified case out of 83 diffuse-type cancers (48) . Somatic mutations in the ERBB2 kinase domain have been reported in lung, colorectal, gastric and breast cancers (19, 49, 50) . Among them, oncogenic roles of the specific small insertion in the ERBB2 kinase domain (G776in-sYVMA), which was discovered in non-small cell lung cancers, have been extensively studied (51, 52) , but functional significance of other rare somatic mutations including the one detected in this study remains to be determined. A recent resequencing analysis in lung adenocarcinoma has identified four non-synonymous mutations in HCK (three of them are located in the kinase domain) and a highly correlation (next to EGFR) has been observed between the mutations and copy number gain in HCK (53), consistent with our results and strongly supporting its oncogenic function as well. HCK belongs to the SFKs and is implicated in the downstream activation of multiple oncoproteins such as BCL-ABL and TEL-ABL chimeras in leukemia (54) . Its chromosomal gain has been associated with poor prognosis in patients with pancreatic cancer, and therefore HCK may also play a role in solid tumors (30) . HDs were observed in two TK regions (JAK2 and TEK) in a primary specimen (GC114) and a cell line (HSC58), respectively (Table III) . HD of TEK gene region in HSC58 has been reported in a previous CGH analysis of gastric cell lines, which analyzed the same cell line in this study (7) . HDs of JAK2 region have not been reported in GC or any other type of cancer.
When comparing these genetic alterations with tumor histology, PTK7 amplification was observed only in the intestinal-type GC (GC008, GC092, GC120 and GC045), and both somatic mutation and high-level amplification of the TIE1 gene were identified in only poorly differentiated intestinal-type GC (GC027 and GC129). Because of the small number of analyzed cases in the current study, the relationship between genetic alterations and tumor histology should be validated in a larger set of case, but our results suggest the existence of distinct oncokinome profiles between the intestinal and diffuse-type GC.
In conclusion, our study represents the first systematic genetic (sequence and copy number) analysis of TK genes in poorly differentiated GCs and has identified potentially oncogenic TKs including novel ones. Since our mutation search was limited to the kinase domain, further sequence analyses of additional protein-encoding regions including the juxta-membrane region and the extracellular domain, whose alterations positively or negatively regulate the kinase activity (55), will help to reveal a broader profile of the onco-kinome in GC. Moreover, recent advances in sequencing technology (56) should allow resequencing of the exome (all protein-encoding exons) or the whole cancer genome in the near future. In this sense, the present study paves the way to a comprehensive understanding of the GC genome.
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